Cardiac Anodal Biphasic Pacing
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Boston Medical Center
- Study ID
- NCT07173777
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cardiac Pacing
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cardiac Waveform Generator — DEVICEA pacing device that allows for programmable pulse waveforms to generate a predefined set of anodal biphasic waveforms. It possesses a battery-powered floating point gate array (FPGA) using software that allows flexibility in waveform configuration.
Study Details
The goal of this study is to test a new pacing method called anodal biphasic pacing (ABP) to determine if this pacing works as well-or better-than current pacing methods. This new method may improve how the heart works and reduce some of the problems caused by regular pacing. Current implantable pacemakers use a monophasic cathodal waveform to stimulate the heart. Monophasic cathodal pacing (MCP) waveforms slow conduction, impair contractility, cause inflammation, increase risk of atrial fibrillation, heart failure, and mortality. Anodal biphasic pacing (ABP) is an alternative waveform that can stimulate the heart. ABP preconditions the heart and then initiates cardiac contraction. ABP may address the limitations of MCP.
Key Dates
- Start date
- Jul 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 108 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Cohort ACardiac patients who are undergoing interventional cardiac procedure including electrophysiology (EP) with planned retrograde left ventricular access or diagnostic coronary catheterization.
- Experimental: Cohort BPatients who have pacing indication and are undergoing routine generator exchange of dual chamber cardiac implantable electronic device (CIED).
- Experimental: Cohort CPatients who are undergoing new implant or generator exchange of CIED with cardiac resynchronization therapy.
Primary Outcome Measure
Clinically significant maximum rate of pressure change maximum rate of pressure change within the left ventricle during its contraction phase- dP/dtmax. [ Time Frame: about 30 minutes ]
Central Contacts
- Robert Helm, MD617-638-8985
- Denise Fine, BS617-638-8716
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Boston Medical Center | Boston | Massachusetts | 02118 | Robert Helm, MD Denise Fine, BS |